PROTEOMICS SHARED RESOURCE Director: Larry David, Ph.D. ABSTRACT/PROJECT SUMMARY The Knight Cancer Institute (Knight) sponsored Proteomics Shared Resource provides advanced tools and expertise in mass spectrometry to determine the identity, abundance, and modifications occurring in proteins. These analyses are crucial to understanding the cause of cancer and devising improved treatments for the disease. The resource supports a wide array of quantitative measurements including: detection of differential protein abundance in complex cell lysates derived from primary tumors, cell lines, cultured tumor organoids and patient-derived xenograft samples; detection of post-translation modifications, such as phosphorylation, acetylation, ubiquitination, methylation and O-GlycNAcylation, measurement of newly synthesized proteins; examination of protein/protein interactions; and, characterization of protein structure. The facility is a university- wide resource that leverages strong financial and administrative support from the institution to enhance cancer research across campus and sister institutions in a collaborative environment. It employs six highly trained individuals, five at the Ph.D. level, and maintains four mass spectrometer systems, one that is a state-of-the-art high-resolution Orbitrap Fusion instrument. Two of the staff provide full-time informatics support, which has a key role in the success of the facility. In addition, the Proteomics Shared Resource benefits from participation in the OHSU Pacific Northwest National Laboratory for Integrated Omics, which provides full access to expertise and instrumentation available through the NIGMS BioTechnology Research Resource in Proteomics at Pacific Northwest National Laboratory. Funds from this CCSG grant provide 10% salary support for the facility director, and 10% salary support for the associate director. The Proteomics Shared Resource will continue to work with the Knight and other OHSU stakeholders to identify and implement new technologies and assays that meet new research opportunities and evolving needs, including close collaboration with the Knight in providing tools and support needed by the new Knight early detection initiative.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-22
Application #
9968105
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019

Showing the most recent 10 out of 277 publications